SureTrader SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

Add TBIO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 8/28/2015 2:13:03 PM - Followers: 29 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#603   Volume EXPLODING! TBIO Tstorm 08/28/15 02:13:03 PM
#602   Looking good! This could be the beginning alphaInvestor2 08/28/15 02:02:33 PM
#601   1.25 falling, here we go! TBIO Tstorm 08/28/15 01:56:18 PM
#600   1.24 falling! If we break 1.26 it should Tstorm 08/28/15 01:22:02 PM
#599   The SS is still in our favor IMO. alphaInvestor2 08/28/15 11:48:11 AM
#598   That would be great! alphaInvestor2 08/28/15 11:26:12 AM
#597   Looking much stronger today after this mornings selling. Tstorm 08/28/15 11:11:35 AM
#596   Hardly any undercutting today, maybe they finished the Tstorm 08/28/15 10:49:58 AM
#595   As usual they sell into the buying...... Hard Tstorm 08/28/15 10:11:53 AM
#594   Big volume right out of the gate.... Lets Tstorm 08/28/15 09:38:36 AM
#593   This news means profitability. I think FDA alphaInvestor2 08/27/15 01:48:05 PM
#592   They have to be selling shares. Im convinced Tstorm 08/27/15 10:01:47 AM
#591   Great news and still can`t hold the gains.... Tstorm 08/27/15 09:58:24 AM
#590   HUGE NEWS OUT!!!! TBIO Tstorm 08/27/15 07:41:50 AM
#589   All we need is the big news$$$$ alphaInvestor2 08/26/15 03:29:05 PM
#588   Any big lot that hits the ask never Tstorm 08/26/15 01:20:26 PM
#587   Now were moving on up.... Tstorm 08/26/15 11:05:24 AM
#586   Couldn't agree more. alphaInvestor2 08/26/15 10:33:15 AM
#585   Same BS different day...... Hard to believe! Tstorm 08/26/15 10:09:05 AM
#584   I know right!?! Good news = more alphaInvestor2 08/25/15 03:15:28 PM
#583   Nothing ever changes here, AMAZING!!! Tstorm 08/25/15 12:53:25 PM
#582   1.25 on the ask now Tstorm 08/24/15 10:27:56 AM
#581   Nice. Hoping for approval asap$ alphaInvestor2 08/24/15 08:46:06 AM
#580   1.37 printing pre-market Tstorm 08/24/15 08:32:13 AM
#579   Nice close today! Tstorm 08/21/15 04:05:25 PM
#578   Transgenomic: Pharmaceutical And Biotechnology Companies Tstorm 08/21/15 02:47:35 PM
#577   NEWS OUT!!! Tstorm 08/21/15 02:45:37 PM
#576   1.23 printing! If this can get moving in Tstorm 08/21/15 02:09:44 PM
#575   True. Thanks for the positive thoughts on alphaInvestor2 08/20/15 06:48:45 PM
#574   good news out today. i see you are ash111 08/20/15 04:40:38 PM
#573   Not at all.NASDAQ down 141 points. today's news ash111 08/20/15 04:14:36 PM
#572   I hate to say it but it looks Tstorm 08/20/15 03:55:37 PM
#571   Very sad. alphaInvestor2 08/20/15 01:52:10 PM
#570   Major dumping once again........ I dont know how Tstorm 08/20/15 01:06:13 PM
#569   Total BS going on here.... Hard to watch Tstorm 08/20/15 12:07:29 PM
#568   about 7m float and 15m market value are ash111 08/20/15 11:09:41 AM
#567   No doubt. Whoever is here now is buying alphaInvestor2 08/20/15 10:41:00 AM
#566   that's what i expected to hear.nice one here. ash111 08/20/15 10:40:12 AM
#565   We are hoping for FDA approval news asap. alphaInvestor2 08/20/15 10:39:29 AM
#564   it's usual with biotech companies. what do you ash111 08/20/15 10:16:52 AM
#563   I agree i like what i see here. Tstorm 08/20/15 10:15:12 AM
#562   just doing my DD so far liking what ash111 08/20/15 10:10:45 AM
#561   That still means they sold 1.7 million shares Tstorm 08/20/15 10:09:17 AM
#560   past 10Q almost the same O/S.As of April ash111 08/20/15 10:04:31 AM
#559   What about the warrants being sold into the Tstorm 08/20/15 10:03:34 AM
#558   i have noticed the float is very low. ash111 08/20/15 10:00:43 AM
#557   Ask size gets hit and size never changes......... Tstorm 08/20/15 09:56:33 AM
#556   Undercutting the ask again today.... When will it Tstorm 08/20/15 09:55:59 AM
#555   Nice bid support building today. Lets see if Tstorm 08/20/15 09:50:48 AM
#554   nice news out.Transgenomic Showcases How Multiplexed ICE COLD-PCR™ ash111 08/20/15 09:47:02 AM